FOR MANY YEARS there has been controversy over the incidence of thyroid dysfunction in patients with breast cancer. Several studies have revealed elevated blood levels of thyroid-stimulating hormone (TSH) in breast-cancer patients (Mittra & Hayward, 1974; Rose & Davis, 1978) and in a recent report (Aldinger et al., 1978) 36% of patients were found to have raised blood TSH levels. Others, however, have found abnormal TSH concentrations less frequently (Adami et al., 1978) . It has been suggested that reduced thyroid function may have a role in the development and progression of breast cancer, and the American Thyroid Association has called for carefully designed and controlled studies of a possible relation between the thyroid and cancer of the breast in humans (Gorman et al., 1977) . We report here the results of a large study to assess thyroid function in patients with benign and malignant breast disease.
We studied 162 Histological proof of the diagnosis was obtained in all patients. Blood was taken from 147 of the cancer group and from 17 of the benign group before surgical removal of the tumour. In the remaining patients blood was taken 24 h after surgery. Serum was stored at -20°C before measurement, by immunoassay, of serum TSH concentration (mU/l), serum triiodothyronine (T3) concentration (nM) and serum thyroxine (T4) concentrations (nM) as previously described (Shalet et al., 1975) . The sensitivity of the TSH assay was 0 5 mU/l. TSH concentrations greater than 6 mU/l were defined as being elevated. This level represented 2 standard deviations above the mean in the 72 controls. Statistical evaluation was by one-factor analysis of variance followed by comparison of all pairs of means at a reduced significance level (1.7%).
Abnormal thyroid function tests were found in 4/162 patients with cancer, 5/60 patients with benign breast disease and 6/72 controls. One patient with cancer was clinically and biochemically thyrotoxic, but in all the others the abnormality was of a raised TSH concentration with normal T3 and T4 levels. Excluding these patients and controls, mean serum TSH, T3 and T4 Table. There was no difference in mean TSH concentration between the cancer and control groups, but the benign group had a significantly higher mean TSH concentration than the other two groups (P < 0 001). There was no difference in mean T3 concentration between the benign and cancer groups or between the control and cancer groups, but T3 in the benign group was significantly lower than in the other two groups together (P=0.012). There was no difference in mean T4 concentrations between the benign and cancer groups, but T4 was significantly lower in the control than in the other two groups (P < 0.001).
Our study is one of the largest reported, and is of value because the patients with breast cancer were consecutive and unselected. To our knowledge, no other study has used for comparison a group of patients with benign breast disease as well as a control group.
We found no increase in the incidence of thyroid dysfunction in patients with breast cancer compared to patients with benign breast disease or to controls. Clearly abnormal tests were found in only 2.5% of the breast-cancer patients, compared to 8.5% of the control and benign breast disease subjects. Comparison of the tests within the normal range gives no indication whatever of any trend to abnormality in cancer patients. A raised TSH concentration is a sensitive indicator of impaired thyroid function (Schimmel & Utiger, 1977) . We conclude that thyroid dysfunction was not associated with the development of breast cancer in our patients.
A study of T3 and T4 concentrations after surgery has shown acute changes, and this might explain some of the differences in hormone concentrations in the benign group, 70% of whom had recently been operated on, compared to the cancer and control groups (Chan et al., 1978) . In the same study TSH concentrations showed a transient but insignificant rise after anaesthesia.
Changes are also seen in many chronic non-thyroid diseases. Low serum T3 concentrations and occasional minimally elevated TSH concentrations with slightly increased TSH responses to thyrotrophinreleasing hormone are found (Schimmel & Utiger, 1977) . Low T3 concentrations and high TSH concentrations in patients with malignant lymphoma have been demonstrated (Brinckmeyer et al., 1977) . The abnormalities were more prominent in patients with advanced than with earlystage disease, and were thought to be secondary to altered peripheral metabolism of thyroid hormones, not due to a primary abnormality in the pituitarythyroid axis. Some of the thyroid-function abnormalities reported elsewhere in breast cancer may be explained by the same mechanisms. Our patients all had operable breast cancer, and continuing analysis of thyroid function may reveal changes in hormone levels in relation to the development of metastatic disease.
